# First Line Therapy for Patients With Metastatic Breast Cancer

> **NCT00456846** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 123 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT00456846
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02-01
- **Primary completion:** 2012-12-11
- **Final completion:** 2013-05-31
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456846, "First Line Therapy for Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00456846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*